127 related articles for article (PubMed ID: 12363470)
1. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
Brain J; Saksena A; Laneuville P
Leuk Res; 2002 Nov; 26(11):1011-6. PubMed ID: 12363470
[TBL] [Abstract][Full Text] [Related]
2. Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership.
Ilaria R
Leuk Res; 2002 Nov; 26(11):971-3. PubMed ID: 12363461
[No Abstract] [Full Text] [Related]
3. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
4. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
[TBL] [Abstract][Full Text] [Related]
5. Measurement of genomic instability in preleukemic P190BCR/ABL transgenic mice using inter-simple sequence repeat polymerase chain reaction.
Brain JM; Goodyer N; Laneuville P
Cancer Res; 2003 Aug; 63(16):4895-8. PubMed ID: 12941812
[TBL] [Abstract][Full Text] [Related]
6. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Mishra S; Zhang B; Groffen J; Heisterkamp N
Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
[TBL] [Abstract][Full Text] [Related]
7. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
8. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
9. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
10. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
11. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Hofmann WK; Jones LC; Lemp NA; de Vos S; Gschaidmeier H; Hoelzer D; Ottmann OG; Koeffler HP
Blood; 2002 Mar; 99(5):1860-2. PubMed ID: 11861307
[TBL] [Abstract][Full Text] [Related]
12. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
Barthe C; Gharbi MJ; Lagarde V; Chollet C; Cony-Makhoul P; Reiffers J; Goldman JM; Melo JV; Mahon FX
Br J Haematol; 2002 Oct; 119(1):109-11. PubMed ID: 12358910
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
Kaur P; Feldhahn N; Zhang B; Trageser D; Müschen M; Pertz V; Groffen J; Heisterkamp N
Mol Cancer; 2007 Oct; 6():67. PubMed ID: 17958915
[TBL] [Abstract][Full Text] [Related]
14. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells.
Kawaguchi Y; Jinnai I; Nagai K; Yagasaki F; Yakata Y; Matsuo T; Kuriyama K; Tomonaga M
Leukemia; 2001 Apr; 15(4):590-4. PubMed ID: 11368361
[TBL] [Abstract][Full Text] [Related]
15. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
16. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
von Bubnoff N; Veach DR; Miller WT; Li W; Sänger J; Peschel C; Bornmann WG; Clarkson B; Duyster J
Cancer Res; 2003 Oct; 63(19):6395-404. PubMed ID: 14559829
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
19. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
